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HER-2/neu (c-erbB-2) proto-oncogene encodes a transmembrane tyrosine/kinase receptor with homology to the epidermal growth factor receptor family, 1, 2) and is overexpressed on breast and ovary cancers, as well as uterine cervical carcinomas. [3] [4] [5] [6] HER-2/neu overexpression induces transformation and tumorigenesis of NIH3T3 7) and was correlated with histological grade and disease stage as an indicator of poor prognosis. [8] [9] [10] The anti-HER-2/neu humanized antibody Trastuzumab recognizes a carbohydrate epitope on the extracellular domain of HER-2/ neu and anti-HER-2/neu antibody suppresses in vitro proliferation of several human solid tumor cell lines. [11] [12] [13] Anti-HER-2/neu antibody action is partially mediated by an antagonistic effect on signal transduction 11, 14) and partially by an anti-tumor effect via antibody-dependent (effector) cell-mediated cytotoxicity (ADCC). 15, 16) Therefore, it can be speculated that the anti-HER-2/neu antibody Trastuzumab also exerts its antitumor effect through these mechanisms. Trastuzumab has been used to treat HER-2/neu-overexpressing tumors in clinical trials, [16] [17] [18] [19] and showed an overall response of 11.6%. 20) Combination therapy with conventional chemotherapeutic agents is now being evaluated clinically in order to increase the anti-tumor activity of anti-HER-2/neu antibodies. 21) It is important to select an appropriate partner for combination therapy. Trastuzumab reportedly enhances the anti-tumor effect of paclitaxel and doxorubicin by affecting the cell cycle distribution. 21, 22) Cisplatin (CDDP) is also considered as a possible partner for combination therapy with Trastuzumab because anti-HER-2/neu antibody interferes with DNA repair following cisplatin-mediated DNA damage [23] [24] [25] [26] [27] and CDDP has actually been used in combination therapy with Trastuzumab clinically. 18, 19, 27) However, it remains unclear whether ADCC and an antagonistic effect initiated by Trastuzumab are responsible for the combination effect and whether the chemotherapeutic agents inhibit the ADCC activity of Trastuzumab. In this study, we examined the combination effect of Trastuzumab and CDDP in the presence of effector cells for ADCC and demonstrated that CDDP alone did not affect the viability of human peripheral blood mononuclear cells (PBMCs), suggesting that ADCC by PBMCs is not affected by CDDP. On the other hand, Trastuzumab, in the presence of PBMCs (10 effector: target ratio), reduced the CDDP IC 50 values in HER-2/neu-overexpressing tumor cells to less than 0.20-fold as compared with the IC 50 value of CDDP alone. This suggests that, in combination therapy, the ADCC activity of Trastuzumab is not affected by any influence of CDDP on PBMCs.
MATERIALS AND METHODS
Cell lines and cell culture The cell lines used were human solid-cancer cell lines including PC-14 (human non-small cell lung cancer), JRST (gastric cancer), BT-474 (breast cancer), SK-Br-3 (breast cancer), and SKOV-3 (ovarian carcinoma). PC-14 was donated by Dr. Y. Hayata (Tokyo Medical University, Tokyo). JRST, BT-474, and SK-Br-3 were obtained from the ATCC (Rockville, MD). SKOV-3 was kindly donated by Dr. K. H. Cowan (National Cancer Institute, Bethesda, MD). PC-14 was cultured in RPMI-1640 medium (Gibco, Grand Island, NY), others were cultured in MEM (Gibco) supplemented with 10% heat-inactivated fetal bovine serum, penicillin (100 units/ml), and streptomycin (100 µg/ml) at 37°C in a humidified 5% CO 2 atmosphere. Antibodies and anti-tumor compounds Trastuzumab was donated by Nippon Roche, Ltd. (Tokyo). Cisplatin (CDDP) was purchased from Nippon Kayaku Co. (Tokyo).
Analysis of HER-2/neu-expression For indirect immunofluorescence, 1×10
6 tumor cells were incubated with 10 mg/ml Trastuzumab diluted with 1% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) (w/v) at 4°C for 1 h. After the first reaction, cells were washed with PBS including 1 mM ethylenediaminetetraacetic acid and incubated for 1 h at 4°C with 10 µg/ml fluoresceinconjugated anti-human IgG (Vector, Burlingame, CA) diluted with 1% BSA-PBS. After the second antibody reaction, cells were washed with PBS twice and resuspended in 2% formaldehyde PBS (v/v). Human IgG (Sigma, St. Louis, MO) was used as a control. The reactivity in 2×10 4 cells was measured using FACScan (Becton Dickinson, Mansfield, MA) and analyzed by Cell Quest (Becton Dickinson). Negative, low, and high expression levels of HER-2/neu were defined as ratios of flow-cytometric intensity less than 2, 2-10, and over 10, respectively. Chromium ( 
28)
Growth-inhibitory effect of Trastuzumab and CDDP Fifteen hundred tumor cells/well were cultured in 96-well microtiter plates in the presence of 0, 0.25, 2.5 µg/ml Trastuzumab and 0-50 µM CDDP for 72 h. After exposure to Trastuzumab and/or CDDP, MTT reagent was added, followed by a 4-h incubation.
29) The absorbance at 630-562 nm was measured with an EL340, 96-well microtiter plate reader ("Bio-Tek" Instruments, Winooski, VT) and % cell growth inhibition was calculated from the absorbance value of untreated cells (A), the absorbance value of treated cells (B) and the absorbance value of medium alone (C) as follows; (B−C)/(A−C)×100. Cell cycle analysis One million cells were cultured in the medium including 0-2.5 µg/ml Trastuzumab for 24-72 h. Cells were collected, fixed in 70% ethanol and stocked at −20°C until analysis. Samples were treated with an ethanol gradient to remove ethanol. RNA was removed by treatment with 0.1 mg/ml RNase in PBS (w/v) for 1 h at 37°C. The cells were stained with 10 mg/ml propidium iodide in PBS (w/v) for 1 h at 4°C. A total of 2×10 4 cells were measured by flow cytometry and analyzed using Modefit (Becton Dickinson). Viability of cultured PBMCs PBMCs were cultured in medium for 7 days, and dead PBMCs were detected microscopically using trypan-blue dye. PBMCs (3.75×10 3 , 7.5×10 3 , 15×10 3 or 30×10 3 ) were cultured in a 96-well microtiter plate for 3 days in the presence of 0-50 µM CDDP. The E/T ratio was 2.5, 5, 10, or 20 at 1500 tumor cells. After incubation, the absorbance value at 630-562 nm was measured using EL340. MTT assay for Trastuzumab-mediated ADCC For analysis of the combination effect with ADCC and CDDP we analyzed the ADCC activity of Trastuzumab using MTT assay. [30] [31] [32] Fifteen hundred tumor cells per well were exposed to 0-5 µg/ml Trastuzumab and 0-50 µM CDDP in the presence of PBMCs at an E/T ratio of 20 for 72 h. The absorbance value at 630-562 nm was measured using an EL340 96-well microtiter plate reader. NK activity was calculated from the absorbance value of the cells cultured without Trastuzumab, CDDP, and PBMCs (A), the absorbance value of cells cultured with PBMCs (B), the absorbance value of medium alone (C), and the absorbance value of PBMCs 
RESULTS

Expression of HER-2/neu on human cancer cell lines
The expression of HER-2/neu was evaluated in terms of the ratio of average intensity to the control intensity using human IgG in flow-cytometric analysis. PC-14 cells expressed low levels of reactive HER-2/neu on the cell surface. JRST and BT-474 cells expressed more than 10-fold higher levels, and SK-Br-3 and SKOV-3 cells expressed more than 20-fold higher levels than PC-14 ( Fig. 1, A-E) . Viability of PBMCs exposed to CDDP The viability of PBMCs detected by trypan-blue staining did not change significantly until 4 days of culture ( Fig. 2A) . In the MTT assay, 7500 and 3750 PBMCs had undetectable absorbance (less than 0.01) (Fig. 2B) . Totals of 30 000 and 51 Cr release assay using 25% human serum. CDC activity was not detected in the concentration range of 0.05-5.00 µg/ml Trastuzumab (n=3). ND, not determined. (Fig. 2B) . Trastuzumab-mediated ADCC and CDC activity IgGtype antibodies containing the Fc portion are usually clinically active through immunological cytotoxicity via ADCC or CDC. Therefore we examined ADCC activity against 51 Cr-labeled cancer cells as targets using Trastuzumab and human PBMCs containing NK cells and monocytes with Fc receptor. We also examined CDC activity against 51 Cr-labeled cancer cells using Trastuzumab and human serum containing human complement. Percent ADCC and %CDC were calculated as described in "Materials and Methods." A cytotoxic effect of Trastuzumab via ADCC by human PBMCs and Trastuzumab was detected against all HER-2/neu-overexpressing cells at 0.5 µg/ml of Trastuzumab. On the other hand, no CDC-mediated cytolytic effect of human complement and Trastuzumab against any of the cells was observed even at 5 µg/ml of Trastuzumab (Fig. 1) . Growth-inhibitory effect of Trastuzumab alone Trastuzumab (2.5 µg/ml for 72 h) showed more than 10% growth-inhibitory effect as compared with the control (without Trastuzumab) against JRST, BT-474, and SK-Br-3 cells, as determined by MTT assay. BT-474 cells were most sensitive to the Trastuzumab-induced growth-inhibitory effect. Survival ratios of these cells at 0.25 and 2.5 µg/ml Trastuzumab were 0.71 and 0.57, respectively. On the other hand, SKOV-3 cells were the least sensitive to the growth-inhibitory effect of Trastuzumab (Table I) . Cell lines sensitive to Trastuzumab showed dose-dependent growth inhibition, but no correlation was detected between HER-2/neu expression and growth inhibition. The values of Pearson's correlation coefficient at 2.5 and 0.25 µg/ml Trastuzumab were 0.181 and 0.141, respectively. Evaluation of ADCC by MTT assay We evaluated the ADCC activity using MTT assay in advance of analysis of the combination effect with ADCC and CDDP. When 15 000 PBMCs and 1500 target tumor cells were incubated in the medium containing 1.0 µg/ml Trastuzumab, the %ADCC values against PC-14, JRST, BT-474, SK-Br-3, and SKOV-3 determined by MTT assay were 9 (Fig. 3) . The correlation coefficient between MTT assay and 51 Cr release assay for ADCC, at 1.0 µg/ml Trastuzumab, was 0.939 at an E/T ratio of 10. SKOV-3 1.00±0.05 1.01±0.17 1.01±0.14 a) Survival ratio±SD of cells determined as compared with the control (0 µg/ml) Trastuzumab using 72 h exposure to 0-2.5 µg/ml Trastuzumab as described in "Materials and Methods." b) Cell growth was significantly inhibited (P<0.05, n=3, Student's t test). growth-inhibitory effect of CDDP, the sensitivity of HER-2/neu-overexpressing cells to CDDP was analyzed by MTT assay with or without 0.25 or 2.5 µg/ml Trastuzumab. We evaluated relative resistance to CDDP as the change of sensitivity because the cancer cell lines had different sensitivity to CDDP alone (4 30 . The direct growth-inhibitory effect of Trastuzumab seems to be masked by the strong cytotoxic effect of a high concentration of CDDP (Table II) (Table  III) . Under the condition of E/T=5 and E/T=10, the IC 50 relative resistance values in the HER-2/neu-overexpressing cells were less than 0.25 and less than 0.20, respectively. The IC 30 relative resistance values at the E/T ratio of 10 were <0.2 in all cell lines (Table III) . Exposure to CDDP at less than 12.5 µM did not affect the viability of PBMCs in vitro (Fig. 2B) . These results indicate that the immunological cytotoxicity of Trastuzumab via PBMCs produces a strong anti-tumor effect in combination with CDDP in vitro.
Effects of Trastuzumab on CDDP-induced growth inhibition To clarify whether Trastuzumab increases the
DISCUSSION
It is difficult to evaluate the anti-tumor activity of the antibody itself in vitro because the ADCC is mediated by effector cells. Trastuzumab showed high ADCC activity during a 6-h period in HER-2/neu-expressing cell lines (Fig. 1, F-J) . When the direct growth-inhibitory effect of Trastuzumab against adhesive cells was examined by MTT assay after a 72-h incubation, Trastuzumab alone did not inhibit the growth by more than 30% and IC 30 could not be determined, except for BT-474 (Table I) . When Trastuzumab was combined with other cytotoxic agents including CDDP, it was difficult to evaluate the combined effect by using conventional in vitro techniques such as the isobologram and the combination index. 33, 34) It was also difficult to analyze the ADCC of Trastuzumab in vivo because the ADCC activity of a humanized antibody is less in mice. 28, 35) Therefore, in vitro analysis of the antitumor effect of the antibody in the presence of human effector cells for ADCC is useful as a pre-clinical test for a humanized antibody combined with chemotherapeutic agents. The in vitro MTT assay for ADCC was validated by the good correlation with the 51 Cr release assay results (Fig. 3) . We demonstrated that the cytotoxic effect of Trastuzumab is mediated by ADCC, which in turn is influenced by the status of HER-2/neu expression on the tumor cell surface. ADCC activity was correlated with HER-2/neu expression measured by flow cytometry (Fig. 1) . In combination with CDDP, Trastuzumab-induced ADCC was not inhibited by a concentration of CDDP sufficient to inhibit tumor cell growth. This might be due to the lower sensitivity of PBMCs to CDDP. The results suggest that the efficacy of ADCC would not be diminished if Trastuzumab is combined with CDDP.
A supra-additive effect of combination therapy with CDDP regimens is often explained by the inhibition of repair of drug-induced DNA damage. [36] [37] [38] It was reported that modulation of anti-HER-2/neu antibody TAb-250 was associated with inhibition of DNA repair, 23, 24, 36) and it has been shown that Trastuzumab interferes with repair of CDDP-induced damage. 27) In addition, Baselga et al. reported a synergistic anti-tumor effect using Trastuzumab and chemotherapeutic agents in vivo. 21) Our results with BT-474 and JRST (Table II) support increased sensitivity of these cell lines to CDDP. However, an HER-2/neuoverexpressing cell line, SKOV-3, did not show a remarkable increase in sensitivity to CDDP (Table II) and the cell cycle distribution of SKOV-3 exposed to Trastuzumab was not greatly changed (data not shown).
CDDP at 12 µM showed no cytotoxicity towards human PBMCs. Therefore, the combination effect of Trastuzumab and CDDP was considered to have been due to the additive effects of ADCC induced by Trastuzumab and cytotoxicity induced by CDDP (Figs. 1, 3 and Table III) . We considered that Trastuzumab-mediated ADCC is mainly involved in the synergistic mechanism, because the synergistic effect was observed only in the presence of PBMC.
The influence of CDDP on the ADCC activity remains unclear. However, the synergistic effect with Trastuzumab was observed only with CDDP when preliminarily experiments were done using several cytotoxic agents (data not shown). The optimum selection of anticancer agents should be further studied.
In the clinical situation, important determinants of the therapeutic benefit of combination therapy with Trastuzumab and chemotherapeutic agents may include not only the expression of HER-2/neu and cell-cycle regulatory molecules, but also the patient's ADCC effector activity.
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